secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001493152-25-017627
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies closes $1.8M registered direct offering of 720K shares at $2.50/share
--------------------------------------------------------------------------------

- Issued 720,000 shares of common stock at $2.50/share; gross proceeds of ~$1.8M before fees.
- Net proceeds to fund working capital, support growing sales of CyPath® Lung, and general corporate purposes.
- Officers and directors subject to 60-day lock-up; company restricted from further equity issuance until Nov 14, 2025.
- WallachBeth Capital acted as sole placement agent; received 8.0% cash fee plus up to $75K expenses.
- Offering closed on October 9, 2025; shares sold under effective shelf registration statement on Form S-3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225017627/0001493152-25-017627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225017627/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer